A new Ebola vaccine: the journey so far

GSK shipped first batch

Initial trials suggest

candidate vaccine

benefit risk profile

has acceptable

Financial support ensures vaccine

development stavs

£11.1m European Commission (EC)

£1.1m Swiss Government £2.8m UK partners £8m BARDA

£1.8m Bill & Melinda Gates Foundation

on track

of vaccine to Liberia

Accelerating 10 years to 10 months



Phase II

3,000 healthy adults and children in clinical trials

 Mali. Nigeria. Ghana. Senegal, Cameroon

Mar 2015



Phase III

30,000 volunteers including frontline healthcare workers

Liberia



GSK already collaborating with NIH to develop an Ebola vaccine

First case of current strain of Ebola in **West Africa**

Outbreak recognised as a major incident in Guinea (March 2014), Sierra Leone (May 2014) and Liberia (July 2014)



GSK supports humanitarian aid partners, helping with critical supplies, equipment and training of additional health workers



Doses have been

Jan 2015

Next

steps..

testing: Mali

Switzerla

• UK

testing:

Three countries primarily affected: Guinea

Sierra Leone

Liberia

• Liberia testing:

Cameroon

Ghana

Mali

Nigeria

Senegal

Mar 2014

Grant from UK partners enables manufacture of new vaccine lots

On 8 August, WHO declared the epidemic to be a "public health emergency of international concern."

UK partners

- Wellcome Trust
- Medical Research Council (MRC) UK Department for International
- Development (DFID)

Aug 2014

GSK, together with private and public partners, form international consortium to accelerate the development of candidate vaccine



Nov 2014

manufactured

and are ready

to be shipped

Dec 2014

£25m Partners commit

a total of nearly

£25m

Phase I: 200 volunteers

- Mali
- Switzerland
- UK
- USA

10,000

Sept 2014

Multiple trials run in parallel with the development of the manufacturing process. The aim is to have stocks ready if the trials are successful



Quality, safety and efficacy standards are fully observed

GSK begin manufacturing an additional 20.000 doses at the same time as initial clinical trials



GSK begin manufacturing another 10,000 doses



